Skip to main content
. 2024 Dec 5;15:1509342. doi: 10.3389/fgene.2024.1509342

FIGURE 2.

FIGURE 2

BIRC5 expression across different immunosubtypes in pan-cancer. (A) ACC, Adrenocortical Carcinoma; (B) BRCA, Breast Invasive Carcinoma; (C) BLCA, Bladder Urothelial Carcinoma; (D) COAD, Colon Adenocarcinoma; (E) CESC, Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma; (F) ESCA, Esophageal Carcinoma; (G) KIRP, Kidney Renal Papillary Cell Carcinoma; (H) KIRC, Kidney Renal Clear Cell Carcinoma; (I) LUSC, Lung Squamous Cell Carcinoma; (J) LUAD, Lung Adenocarcinoma; (K) LIHC, Liver Hepatocellular Carcinoma; (L) LGG, Brain Lower Grade Glioma; (M) MESO, Mesothelioma; (N) OV, Ovarian Serous Cystadenocarcinoma; (O) PAAD, Pancreatic Adenocarcinoma; (P) PRAD, Prostate Adenocarcinoma; (Q) READ, Rectum Adenocarcinoma; (R) SARC, Sarcoma; (S) STAD, Stomach Adenocarcinoma; (T) TGCT, Testicular Germ Cell Tumors; (U) THCA, Thyroid Carcinoma; (V) UCEC, Uterine Corpus Endometrial Carcinoma (C1: wound healing, C2: IFN-gamma dominance, C3: inflammation, C4: lymphocyte depletion, C5: immune quiet, C6: TGF-b dominance), “Pv” refers to the p-value.